secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001641172-25-021407
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma appoints Lee T. Schalop to Board, reduces shareholder quorum to 33.33%
--------------------------------------------------------------------------------

- Appointed Lee T. Schalop, M.D., former CEO of Oncoceutics (sold to Chimerix for $450M), to the Board effective July 24, 2025.
- Dr. Schalop has extensive biotech and finance background including roles at Morgan Stanley, J.P. Morgan, Credit Suisse.
- Board amended By-laws to reduce stockholder quorum requirement from majority to one-third (33.33%) of shares entitled to vote.
- Amendment to Section 2.07 effective immediately on July 24, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/0001641172-25-021407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-021407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer